name	nt_name	aa_name	multi_aa_name	multiaa_mutation_split_names	start	vcf_gene	chrom_region	mutation_type	dp	obs_sample_size	variant_pop_size	ps_filter	ps_exc	mat_pep_id	mat_pep_desc	mat_pep_acc	ro	ao_by_var_seq	ao	variant_seq	reference_seq	function_category	citation	citation_url	comb_mutation	function_description	heterozygosity	viral_lineages	clade_defining_status	status	voi_designation_date	voc_designation_date	vum_designation_date
c.A-3T	c.A-3T				28271	N	intergenic		12391	436.0	13643						0	T=12391	12391	T	A						False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
c.C-25T	c.C-25T				241	orf1ab	5' UTR		13633	436.0	13643						0	T=13633	13633	T	C						False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
c.C-87T	c.C-87T				27807	ORF8	intergenic		13638	436.0	13643						0	T=13638	13638	T	C						False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
c.CGAGGCCACGCGGAGTACGATCGAGTG29733C	c.*4350_*4375delGAGGCCACGCGGAGTACGATCGAGTG				29733	intergenic	Stem-loop,3' UTR		430	436.0	13643						1	C=429	429	C	CGAGGCCACGCGGAGTACGATCGAGTG						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.3676del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'S3675del', 'F3677del'	11287	orf1ab	ORF1ab		872	872.0	13643			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	G=872	872	G	GTCTGGTTTT						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.A1352A	c.C4056T	p.A1352A			4321	orf1ab	ORF1ab	SILENT	436	436.0	13643			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=436	436	T	C						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.A1707A	c.T5121G	p.A1707A			5386	orf1ab	ORF1ab	SILENT	13207	0.0	13643			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	G=13206	13206	G	T						False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.A2710T	c.G8128A	p.A2710T			8393	orf1ab	ORF1ab	MISSENSE	13207	0.0	13643			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	A=13207	13207	A	G						False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.A2909V	c.C8726T	p.A2909V			8991	orf1ab	ORF1ab	MISSENSE	435	436.0	13643			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	387	T=48	48	T	C						False	BA.2	BA.2=False	VOC		26-Nov-2021	24-Nov-2021
p.A63T	c.G187A	p.A63T			26709	M	M	MISSENSE	13637	436.0	13643	caution	ambiguous,amended				4	A=13633	13633	A	G						False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	6503	0.0	13643						4609	T=1894	1894	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.	False	BA.1	BA.1=False	VOC		26-Nov-2021	24-Nov-2021
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	6503	0.0	13643						4609	T=1894	1894	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1	BA.1=False	VOC		26-Nov-2021	24-Nov-2021
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	6503	0.0	13643						4609	T=1894	1894	T	C	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.	False	BA.1	BA.1=False	VOC		26-Nov-2021	24-Nov-2021
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	6503	0.0	13643						4609	T=1894	1894	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1	BA.1=False	VOC		26-Nov-2021	24-Nov-2021
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	6503	0.0	13643						4609	T=1894	1894	T	C	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is -0.33 kcal/mol (i.e. destabilizing relative to wild type) 	False	BA.1	BA.1=False	VOC		26-Nov-2021	24-Nov-2021
p.A735A	c.C2205T	p.A735A			2470	orf1ab	ORF1ab	SILENT	6575	0.0	13643			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	317	T=6258	6258	T	C						False	BA.1.1	BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D1146D	c.C3438T	p.D1146D			25000	S	S	SILENT	13643	436.0	13643						0	T=13643	13643	T	C						False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D3311D	c.C9933T	p.D3311D			10198	orf1ab	ORF1ab	SILENT	436	436.0	13643			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	0	T=436	436	T	C						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.D343G	c.A1028G	p.D343G			29301	N	N	MISSENSE	6616	0.0	13643						5411	G=1205	1205	G	A						False	BA.1	BA.1=False	VOC		26-Nov-2021	24-Nov-2021
p.D3G	c.A8G	p.D3G			26530	M	M	MISSENSE	13197	0.0	13643						4	G=13193	13193	G	A						False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D405N	c.G1213A	p.D405N			22775	S	S	MISSENSE	261	436.0	13643						1	A=260	260	A	G						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	6621	0.0	13643						0	G=6621	6621	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'A701V'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.	False	BA.1	BA.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'H655Y'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13199	0.0	13643						0	G=13199	13199	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'H69del', 'V70del'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis)."	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'K417N'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'N501Y'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma)."	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P681H'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13199	0.0	13643						0	G=13199	13199	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T95I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	ACE2 receptor binding affinity	Li et al. (2020)	https://doi.org/10.1016/j.cell.2020.07.012		In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	6621	0.0	13643						0	G=6621	6621	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'A701V'	1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1	BA.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'H655Y'	1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13199	0.0	13643						0	G=13199	13199	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'H69del', 'V70del'	1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. 	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'K417N'	2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'N501Y'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P681H'	1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13199	0.0	13643						0	G=13199	13199	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T95I'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	immunosuppression variant emergence	Landis et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1		Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	reinfection	Rani et al. (2021)	https://doi.org/10.1002/jmv.26997	'N440K'	A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y'	Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	tissue specific neutralization	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5		The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	trafficking	Barrett et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1		Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	trafficking	Daniloski et al. (2021)	https://doi.org/10.7554/elife.65365		The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y'	~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'N501Y'	~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20213	872.0	13643						0	G=20213	20213	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y'	9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	trafficking	Ozono et al. (2020)	https://www.nature.com/articles/s41467-021-21118-2		Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	trafficking	Zhang et l. (2020)	https://www.nature.com/articles/s41467-020-19808-4		We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013		Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008		Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'N501Y'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y'	This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	vaccine neutralization efficacy	Zuckerman et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1	'P681H'	No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	6621	0.0	13643						0	G=6621	6621	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'A701V'	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1	BA.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'H655Y'	1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13199	0.0	13643						0	G=13199	13199	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'H69del', 'V70del'	1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'K417N'	1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'N501Y'	1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P681H'	1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13199	0.0	13643						0	G=13199	13199	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T95I'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	viral load	Plante et al. (2020)	https://www.nature.com/articles/s41586-020-2895-3		Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	virion structure	Weissman et al. (2020)	https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2		"Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	virion structure	Yurkovetskiy et al. (2020)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/		"CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	13635	436.0	13643						0	G=13635	13635	G	A	virion structure	Zhang et al. (2020)	https://www.nature.com/articles/s41467-020-19808-4		Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D61L	c.GAT181_183CTC	p.D61L			27382	ORF6	ORF6		436	436.0	13643						1	CTC=434	434	CTC	GAT						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.E31_S33del	c.89_97delGAGAACGCA	p.E31_S33del			28361	N	N		13403	436.0	13643						12	G=13390	13390	G	GGAGAACGCA						False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.E484A	c.A1451C	p.E484A			23013	S	S	MISSENSE	9531	436.0	13643						0	C=9531	9531	C	A	antibody epitope effects	Liu et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.E484A	c.A1451C	p.E484A			23013	S	S	MISSENSE	9531	436.0	13643						0	C=9531	9531	C	A	convalescent plasma escape	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested. Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.E484A	c.A1451C	p.E484A			23013	S	S	MISSENSE	9531	436.0	13643						0	C=9531	9531	C	A	monoclonal antibody serial passage escape	Greaney et al. (2020)	https://doi.org/10.1016/j.chom.2020.11.007		Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.E484A	c.A1451C	p.E484A			23013	S	S	MISSENSE	9531	436.0	13643						0	C=9531	9531	C	A	monoclonal antibody serial passage escape	Starr et al. (2020)	https://doi.org/10.1101/2020.11.30.405472		"""E484A rose in frequency in linkage with F486I, but since E484A is not an escape mutation in our maps it is not shown in other panels"""	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.E484A	c.A1451C	p.E484A			23013	S	S	MISSENSE	9531	436.0	13643						0	C=9531	9531	C	A	monoclonal antibody serial passage escape	Starr et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1		Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.E484A	c.A1451C	p.E484A			23013	S	S	MISSENSE	9531	436.0	13643						0	C=9531	9531	C	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Bamlanivimab (LY-CoV555) lost ~8x binding against this isolated mutation.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.E6597E	c.A19791G	p.E6597E			20055	orf1ab	ORF1ab	SILENT	436	436.0	13643			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only	YP_009725310.1	0	G=436	436	G	A						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.F112F	c.C336T	p.F112F			26858	M	M	SILENT	435	436.0	13643						0	T=435	435	T	C						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.F3677del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'S3675del', '3676del'	11287	orf1ab	ORF1ab		436	436.0	13643			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	G=436	436	G	GTCTGGTTTT						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.F8F	c.C24T	p.F8F			25416	ORF3a	ORF3a	SILENT	436	436.0	13643						295	T=141	141	T	C						False	BA.2	BA.2=False	VOC		26-Nov-2021	24-Nov-2021
p.F924F	c.C2772T	p.F924F			3037	orf1ab	ORF1ab	SILENT	13643	436.0	13643			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=13643	13643	T	C						False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.G1307S	c.G3919A	p.G1307S			4184	orf1ab	ORF1ab	MISSENSE	436	436.0	13643			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	A=436	436	A	G						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.G142D	c.G425A	p.G142D			21987	S	S	MISSENSE	436	436.0	13643	mask	amplicon_drop_or_primer_artefact,back_to_ref				0	A=436	436	A	G	monoclonal antibody serial passage escape	McCallum et al. (2021)	https://doi.org/10.1101/2021.01.14.426475		Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2M28, S2X28, S2X333	False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.G142D	c.G425A	p.G142D			21987	S	S	MISSENSE	436	436.0	13643	mask	amplicon_drop_or_primer_artefact,back_to_ref				0	A=436	436	A	G	monoclonal antibody serial passage escape	Suryadevara et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.19.427324v1		Selected twice in passage with mAb COV2-2489.	False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.G142_Y145delinsD	c.425_433delGTGTTTATT	p.G142_Y145delinsD			21986	S	S		13142	0.0	13643						0	G=13141	13141	G	GGTGTTTATT						False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.G339D	c.G1016A	p.G339D			22578	S	S	MISSENSE	13599	436.0	13643						0	A=13599	13599	A	G	ACE2 receptor binding affinity	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, ACE2 binding affinity increased 0.06 fold	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.G339D	c.G1016A	p.G339D			22578	S	S	MISSENSE	13599	436.0	13643						0	A=13599	13599	A	G	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.3 fold	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.G446S	c.G1336A	p.G446S			22898	S	S	MISSENSE	9177	0.0	13643						7	A=9170	9170	A	G						False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.G496S	c.G1486A	p.G496S			23048	S	S	MISSENSE	13153	0.0	13643						0	A=13153	13153	A	G	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.12 fold	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	13637	436.0	13643						0	T=13637	13637	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	13637	436.0	13643						0	T=13637	13637	T	C	anthropozoonotic events	Esclera et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1		Six minks were intranasally infected with WA1 isolate, all developed this mutation during infection.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	13637	436.0	13643						0	T=13637	13637	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	13637	436.0	13643						0	T=13637	13637	T	C	homoplasy	Borges et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1		In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent. 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	13637	436.0	13643						0	T=13637	13637	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	13637	436.0	13643						0	T=13637	13637	T	C	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 0.87 kcal/mol (i.e. stabilizing relative to wild type) 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		19698	0.0	13643						1	TTA=19693	19693	TTA	CTATACATG	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'V70del'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis)."	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		19698	0.0	13643						1	TTA=19693	19693	TTA	CTATACATG	ACE2 receptor binding affinity	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'V70del', 'N501Y'	This mutation combination causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped  lentivirus, but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed. 	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		19698	0.0	13643						1	TTA=19693	19693	TTA	CTATACATG	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'V70del', 'N501Y'	Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		19698	0.0	13643						1	TTA=19693	19693	TTA	CTATACATG	antibody epitope effects	Rees-Spear et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1	'V70del'	Reduces neutralization by structurally unmapped mAb COVA1-21 (cluster XI).	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		19698	0.0	13643						1	TTA=19693	19693	TTA	CTATACATG	antibody epitope effects	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2	'V70del', 'N501Y'	Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x). PG: these effects are laregly missing in the deletion-alone data	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		19698	0.0	13643						1	TTA=19693	19693	TTA	CTATACATG	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'V70del'	1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. 	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		19698	0.0	13643						1	TTA=19693	19693	TTA	CTATACATG	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'V70del', 'N501Y', 'P681H'	One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		19698	0.0	13643						1	TTA=19693	19693	TTA	CTATACATG	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'V70del', 'N501Y', 'P681H'	Slight neutralization improvement on average in 16 health workers' convalescent sera.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		19698	0.0	13643						1	TTA=19693	19693	TTA	CTATACATG	convalescent plasma escape	Kemp et al. (2020)	https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v1		Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		19698	0.0	13643						1	TTA=19693	19693	TTA	CTATACATG	convalescent plasma escape	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2	'V70del'	Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		19698	0.0	13643						1	TTA=19693	19693	TTA	CTATACATG	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'V70del'	Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		19698	0.0	13643						1	TTA=19693	19693	TTA	CTATACATG	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'V70del', 'N501Y', 'P681H'	These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		19698	0.0	13643						1	TTA=19693	19693	TTA	CTATACATG	environmental condition stability	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'V70del', 'N501Y', 'P681H'	Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		19698	0.0	13643						1	TTA=19693	19693	TTA	CTATACATG	immunosuppression variant emergence	Kemp et al. (2020)	https://doi.org/10.1101/2020.12.14.422555		The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7] Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		19698	0.0	13643						1	TTA=19693	19693	TTA	CTATACATG	symptom prevalence	Snell et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.16.21253377v1	'V70del', 'N501Y'	A higher proportion of cases infected with the B.1.1.7 variant were hypoxic on admission compared to other variants (70.0% vs 62.5%, p	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		19698	0.0	13643						1	TTA=19693	19693	TTA	CTATACATG	symptom prevalence	van Loon et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.15.21255389v1	'V70del', 'N501Y'	"In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P"	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		19698	0.0	13643						1	TTA=19693	19693	TTA	CTATACATG	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'V70del', 'N501Y'	Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, moreso than this combination with the addition of P681H.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		19698	0.0	13643						1	TTA=19693	19693	TTA	CTATACATG	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'V70del', 'N501Y', 'P681H'	Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		19698	0.0	13643						1	TTA=19693	19693	TTA	CTATACATG	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'V70del'	1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		19698	0.0	13643						1	TTA=19693	19693	TTA	CTATACATG	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'V70del', 'N501Y'	The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		19698	0.0	13643						1	TTA=19693	19693	TTA	CTATACATG	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'V70del', 'N501Y', 'P681H'	The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.I3055T	c.T9164C	p.I3055T			9429	orf1ab	ORF1ab	MISSENSE	6629	0.0	13643			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	5918	C=711	711	C	T						False	BA.1	BA.1=False	VOC		26-Nov-2021	24-Nov-2021
p.I3758V	c.A11272G	p.I3758V			11537	orf1ab	ORF1ab	MISSENSE	13206	0.0	13643			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	G=13206	13206	G	A						False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.I4205I	c.C12615T	p.I4205I			12880	orf1ab	ORF1ab	SILENT	870	872.0	13643			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab	YP_009725305.1	0	T=870	870	T	C						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.I5967V	c.A17899G	p.I5967V			18163	orf1ab	ORF1ab	MISSENSE	13638	436.0	13643			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	0	G=13636	13636	G	A						False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1		The K417N mutation decreased the affinity ~4 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	ACE2 receptor binding affinity	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	ACE2 receptor binding affinity	Laffeber et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1		RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface (Kd 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	ACE2 receptor binding affinity	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1		The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	antibody epitope effects	Sun et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1		>20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against IgG1 monoclonal antibody ab1.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs)	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	antibody epitope effects	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		Pseudotyped virus model ablates binding by RBD-directed mAbs CB6 and 910-30 (targeting the inner side of the RBD). Pseudotyped virus model impairs binding by RBD-directed mAbs 4-20 and REGN10933.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 		In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistence P	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.1 fold	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	monoclonal antibody serial passage escape	Starr et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1		Escape mutation against monoclonal antibody LY-CoV016	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		COR-101 lost ~6x binding against this isolated mutation. Estesevimab lost ~100x binding against this isolated mutation.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'N501Y'	COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	pharmaceutical effectiveness	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y', 'D614G'	~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y', 'D614G'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	9456	436.0	13643						4	T=9452	9452	T	G	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is -0.86 kcal/mol (i.e. destabilizing relative to wild type) 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K856R	c.A2567G	p.K856R			2832	orf1ab	ORF1ab	MISSENSE	13207	0.0	13643			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	1	G=13205	13205	G	A						False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.L106F	c.C316T	p.L106F			25708	ORF3a	ORF3a	MISSENSE	6618	0.0	13643						5414	T=1204	1204	T	C						False	BA.1	BA.1=False	VOC		26-Nov-2021	24-Nov-2021
p.L24_A27delinsS	c.71_79delTACCCCCTG	p.L24_A27delinsS			21632	S	S		436	436.0	13643						0	T=436	436	T	TTACCCCCTG						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.L3027F	c.C9079T	p.L3027F			9344	orf1ab	ORF1ab	MISSENSE	436	436.0	13643			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	T=436	436	T	C						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.L3201F	c.C9601T	p.L3201F			9866	orf1ab	ORF1ab	MISSENSE	436	436.0	13643			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	4	T=432	432	T	C						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.L3290L	c.T9870C	p.L3290L			10135	orf1ab	ORF1ab	SILENT	6619	0.0	13643			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	5416	C=1203	1203	C	T						False	BA.1	BA.1=False	VOC		26-Nov-2021	24-Nov-2021
p.L3674_G3676del	c.11018_11026delGTTTGTCTG	p.L3674_G3676del			11282	orf1ab	ORF1ab		13206	0.0	13643			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	A=13206	13206	A	AGTTTGTCTG						False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.L5150L	c.C15450T	p.L5150L			15714	orf1ab	ORF1ab	SILENT	436	436.0	13643			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	T=436	436	T	C						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.L981F	c.C2941T	p.L981F			24503	S	S	MISSENSE	13189	0.0	13643						1	T=13188	13188	T	C						False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N211_L212delinsI	c.632_634delATT	p.N211_L212delinsI			22193	S	S		12701	0.0	13643						1	A=12699	12699	A	AATT						False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	9418	436.0	13643						4	G=9414	9414	G	T	ACE2 receptor binding affinity	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, ACE2 binding affinity increased 0.07 fold	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	9418	436.0	13643						4	G=9414	9414	G	T	antibody epitope effects	Cheng et al. (2021)	https://virologyj.biomedcentral.com/articles/10.1186/s12985-021-01554-8		N501Y substitution decreased the neutralizing and binding activities of CB6 and increased that of BD-23	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	9418	436.0	13643						4	G=9414	9414	G	T	antibody epitope effects	Gaebler et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2		Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	9418	436.0	13643						4	G=9414	9414	G	T	antibody epitope effects	Rappazzo et al. (2021)	https://science.sciencemag.org/content/371/6531/823		Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555. Abolishes binding of mAb ADG-1.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	9418	436.0	13643						4	G=9414	9414	G	T	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	9418	436.0	13643						4	G=9414	9414	G	T	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Class 3 antibody C669 mildly selected for the emergence of the N440K mutation in vitro (in contrast to N440H which caused mild escape in Class 1/2 mAb C653).	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	9418	436.0	13643						4	G=9414	9414	G	T	monoclonal antibody serial passage escape	Weisblum et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf		Positive selection (up to 45% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, eliminated in subsequent passages	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	9418	436.0	13643						4	G=9414	9414	G	T	reinfection	Rani et al. (2021)	https://doi.org/10.1002/jmv.26997	'D614G'	A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	9418	436.0	13643						4	G=9414	9414	G	T	transmissibility	Tandel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.30.441434v1		The N440K variant produced ten times higher infectious viral titers than a prevalent A2a strain,  and over 1000 folds higher titers than a much less prevalent A3i strain prototype in Caco2 cells.  Interestingly, A3i strain showed the highest viral RNA levels, but the lowest infectious titers  in the culture supernatants, indicating the absence of correlation between the RNA content and the infectivity of the sample.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N4992N	c.C14976T	p.N4992N			15240	orf1ab	ORF1ab	SILENT	13207	0.0	13643			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	T=13207	13207	T	C						False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1		The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance. 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	ACE2 receptor binding affinity	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	ACE2 receptor binding affinity	Gamez et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.09.439154v1		The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma)."	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	ACE2 receptor binding affinity	Laffeber et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1		RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.02.428884v1		Reported 10-fold increase in ACE2 binding vs wildtype (Kd 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	ACE2 receptor binding affinity	Motozono et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1		~4-fold increase in binding affinity vs wild type.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	ACE2 receptor binding affinity	Santos and Passos (2021)	https://www.biorxiv.org/content/10.1101/2020.12.29.424708v1		In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	ACE2 receptor binding affinity	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, ACE2 binding affinity increased 0.24 fold	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	ACE2 receptor binding affinity	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed. 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13156	0.0	13643						0	T=13156	13156	T	A	ACE2 receptor binding affinity	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'V70del'	This mutation combination causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped  lentivirus, but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed. 	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	ACE2 receptor binding affinity	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1		The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	ACE2 receptor binding affinity	Zahradnik et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.06.425392		Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	ACE2 receptor binding affinity	Zhu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.11.426269v2		N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	T cell evasion	Reynolds et al. (2021)	https://science.sciencemag.org/content/early/2021/04/29/science.abh1282		Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 		Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13156	0.0	13643						0	T=13156	13156	T	A	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'H69del', 'V70del'	Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	antibody epitope effects	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	antibody epitope effects	Haynes et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1		Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	antibody epitope effects	Klegerman et al. (2021)	https://doi.org/10.1101/2021.04.26.441517		Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	antibody epitope effects	Rees-Spear et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1		Lowered the neutralization potency of mAb COVA1-12 to the limit of the assay. Decrease in potency was observed against the N501Y pseudotype for the cluster IX mAb COVA2-17.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	antibody epitope effects	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2		Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x)	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13156	0.0	13643						0	T=13156	13156	T	A	antibody epitope effects	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2	'H69del', 'V70del'	Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x). PG: these effects are laregly missing in the deletion-alone data	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13156	0.0	13643						0	T=13156	13156	T	A	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'H69del', 'V70del', 'P681H'	One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13156	0.0	13643						0	T=13156	13156	T	A	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'H69del', 'V70del', 'P681H'	Slight neutralization improvement on average in 16 health workers' convalescent sera.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	convalescent plasma escape	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008		0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	convalescent plasma escape	Rathnasinghe et al. (2021)	https://dx.doi.org/10.1101%2F2021.01.19.21249592		In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	convalescent plasma escape	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2		Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13156	0.0	13643						0	T=13156	13156	T	A	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'V70del', 'P681H'	These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1		As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	environmental condition stability	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13156	0.0	13643						0	T=13156	13156	T	A	environmental condition stability	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'V70del', 'P681H'	Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	homoplasy	Flores-Alanis et al. (2021)	https://www.mdpi.com/2076-0817/10/2/184/htm		Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin).	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	immunosuppression variant emergence	Choi et al. (2020)	https://www.nejm.org/doi/full/10.1056/NEJMc2031364		Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'K417N'	COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	pharmaceutical effectiveness	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13156	0.0	13643						0	T=13156	13156	T	A	symptom prevalence	Snell et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.16.21253377v1	'H69del', 'V70del'	A higher proportion of cases infected with the B.1.1.7 variant were hypoxic on admission compared to other variants (70.0% vs 62.5%, p	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13156	0.0	13643						0	T=13156	13156	T	A	symptom prevalence	van Loon et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.15.21255389v1	'H69del', 'V70del'	"In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P"	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'D614G'	Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'D614G'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'D614G'	~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20168	872.0	13643						0	T=20168	20168	T	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'D614G'	~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	trafficking	Motozono et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1		Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully]	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13156	0.0	13643						0	T=13156	13156	T	A	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'V70del'	Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, moreso than this combination with the addition of P681H.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13156	0.0	13643						0	T=13156	13156	T	A	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'V70del', 'P681H'	Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	vaccine neutralization efficacy	Bates et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1		Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	vaccine neutralization efficacy	Edara et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.02.02.21250799v1		1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay. 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	vaccine neutralization efficacy	Jacobson et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2		The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'D614G'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	vaccine neutralization efficacy	Rathnasinghe et al. (2021)	https://dx.doi.org/10.1101%2F2021.01.19.21249592		Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	vaccine neutralization efficacy	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13592	436.0	13643						0	T=13592	13592	T	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type) 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13156	0.0	13643						0	T=13156	13156	T	A	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'V70del'	The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	13156	0.0	13643						0	T=13156	13156	T	A	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'V70del', 'P681H'	The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N679K	c.T2037G	p.N679K			23599	S	S	MISSENSE	13603	436.0	13643						0	G=13603	13603	G	T						False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N764K	c.C2292A	p.N764K			23854	S	S	MISSENSE	12579	436.0	13643						6	A=12573	12573	A	C						False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N856K	c.C2568A	p.N856K			24130	S	S	MISSENSE	13183	0.0	13643						0	A=13183	13183	A	C						False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N969K	c.T2907A	p.N969K			24469	S	S	MISSENSE	13625	436.0	13643						0	A=13625	13625	A	T						False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.P13L	c.C38T	p.P13L			28311	N	N	MISSENSE	13279	436.0	13643						17	T=13262	13262	T	C	T cell evasion	de Silva et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1		Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13).	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.P13L	c.C38T	p.P13L			28311	N	N	MISSENSE	13279	436.0	13643						17	T=13262	13262	T	C	homoplasy	Borges et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1		In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent. 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.P3395H	c.C10184A	p.P3395H			10449	orf1ab	ORF1ab	MISSENSE	13207	0.0	13643			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	0	A=13207	13207	A	C						False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.P3395H	c.GCC10182_10184ACA	p.P3395H			10447	orf1ab	ORF1ab		436	436.0	13643			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	0	ACA=436	436	ACA	GCC						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.P4715L	c.C14144T	p.P4715L			14408	orf1ab	ORF1ab	MISSENSE	13643	436.0	13643			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	2	T=13641	13641	T	C						False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	13603	436.0	13643						0	A=13603	13603	A	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	13603	436.0	13643						0	A=13603	13603	A	C	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 		Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	13603	436.0	13643						0	A=13603	13603	A	C	antibody epitope effects	Haynes et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1		Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	13603	436.0	13643						0	A=13603	13603	A	C	antibody epitope effects	Johnson et al. (2020)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457603/ 		This variant is adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	13603	436.0	13643						0	A=13603	13603	A	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	13175	0.0	13643						0	A=13175	13175	A	C	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'H69del', 'V70del', 'N501Y'	One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	13175	0.0	13643						0	A=13175	13175	A	C	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'H69del', 'V70del', 'N501Y'	Slight neutralization improvement on average in 16 health workers' convalescent sera.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	13175	0.0	13643						0	A=13175	13175	A	C	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'V70del', 'N501Y'	These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	13175	0.0	13643						0	A=13175	13175	A	C	environmental condition stability	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'V70del', 'N501Y'	Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	13603	436.0	13643						0	A=13603	13603	A	C	trafficking	Lubinski et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.06.438731v1		While the introduction of P681H in the SARS-CoV-2 B.1.1.7 variant may increase spike cleavage by furin-like proteases,  this does not significantly impact viral entry or cell-cell spread. We consider that other factors are at play to account  for the increased in transmission and disease severity attributed to this variant of concern (VOC).	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	13603	436.0	13643						0	A=13603	13603	A	C	trafficking	Maaroufi (2021)	https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication		This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry).	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	13603	436.0	13643						0	A=13603	13603	A	C	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing NO statistically significant infection rate change amongst the cells, suggesting that furin cleavage typically used for cell entry is not affected by this change one  amino acid upstream of the RXXR recognition pattern. 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	13175	0.0	13643						0	A=13175	13175	A	C	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'V70del', 'N501Y'	Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	13603	436.0	13643						0	A=13603	13603	A	C	vaccine neutralization efficacy	Zuckerman et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1	'D614G'	No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	13603	436.0	13643						0	A=13603	13603	A	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	13603	436.0	13643						0	A=13603	13603	A	C	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	13175	0.0	13643						0	A=13175	13175	A	C	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'V70del', 'N501Y'	The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.Q19E	c.C55G	p.Q19E			26577	M	M	MISSENSE	13545	436.0	13643						4	G=13541	13541	G	C						False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.Q493R	c.A1478G	p.Q493R			23040	S	S	MISSENSE	13587	436.0	13643						1	G=13586	13586	G	A	antibody epitope effects	Gaebler et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2		Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.Q493R	c.A1478G	p.Q493R			23040	S	S	MISSENSE	13587	436.0	13643						1	G=13586	13586	G	A	antibody epitope effects	Rappazzo et al. (2021)	https://science.sciencemag.org/content/371/6531/823		Massive reduction in binding efficiency vs wild type for mAbs CB6/LY-CoV16 and LY-CoV555.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.Q493R	c.A1478G	p.Q493R			23040	S	S	MISSENSE	13587	436.0	13643						1	G=13586	13586	G	A	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Somewhat resistent to some class 1 (Spike 'up') antibodies tested. Mix of non- to strongly resistent in class 2 antibodies tested.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.Q493R	c.A1478G	p.Q493R			23040	S	S	MISSENSE	13587	436.0	13643						1	G=13586	13586	G	A	convalescent plasma escape	Schmidt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1		Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.Q493R	c.A1478G	p.Q493R			23040	S	S	MISSENSE	13587	436.0	13643						1	G=13586	13586	G	A	monoclonal antibody serial passage escape	Barnes et al. (2020)	https://www.nature.com/articles/s41586-020-2852-1_reference.pdf?origin		The engineered mutation cause 10-fold or more increase in the disassociation constant with C144, C002 and C121 monoclonal antibodies vs. wild type Spike protein RBD domain AAs.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.Q493R	c.A1478G	p.Q493R			23040	S	S	MISSENSE	13587	436.0	13643						1	G=13586	13586	G	A	monoclonal antibody serial passage escape	Starr et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1		Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.Q493R	c.A1478G	p.Q493R			23040	S	S	MISSENSE	13587	436.0	13643						1	G=13586	13586	G	A	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Class 2 mAb C627 modestly selected for the emergence of this mutation in vitro.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.Q493R	c.A1478G	p.Q493R			23040	S	S	MISSENSE	13587	436.0	13643						1	G=13586	13586	G	A	monoclonal antibody serial passage escape	Weisblum et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf		Strong positive selection (up to 37% of supernatant sequences) after two rounds of C135 monoclonal antibody passage, overall 76% switch away from Q493 to K or R	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.Q954H	c.A2862T	p.Q954H			24424	S	S	MISSENSE	13626	436.0	13643						0	T=13625	13625	T	A						False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.R20R	c.A58C	p.R20R			27259	ORF6	ORF6	SILENT	13636	436.0	13643						0	C=13636	13636	C	A						False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.R214_D215insEPE	c.642_643insGAGCCAGAA	p.R214_D215insEPE			22204	S	S		12642	0.0	13643						24	TGAGCCAGAA=12611	12611	TGAGCCAGAA	T						False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.R346K	c.G1037A	p.R346K			22599	S	S	MISSENSE	6578	0.0	13643						6	A=6572	6572	A	G	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.12 fold	False	BA.1.1	BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.R346K	c.G1037A	p.R346K			22599	S	S	MISSENSE	6578	0.0	13643						6	A=6572	6572	A	G	monoclonal antibody serial passage escape	Weisblum et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf		Strong positive selection (up to 53% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, overall 70% switch away from R346 to S, K or M	False	BA.1.1	BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.R408S	c.A1224C	p.R408S			22786	S	S	MISSENSE	221	436.0	13643						0	C=221	221	C	A	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.21 fold	False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.R5716C	c.C17146T	p.R5716C			17410	orf1ab	ORF1ab	MISSENSE	436	436.0	13643			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	0	T=436	436	T	C						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.RG203KR	c.GGG608_610AAC	p.RG203KR			28881	N	N		13639	436.0	13643						0	AAC=13636	13636	AAC	GGG						False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.S135R	c.T405G	p.S135R			670	orf1ab	ORF1ab	MISSENSE	435	436.0	13643			leader protein	nsp1, produced by both pp1a and pp1ab	YP_009725297.1	2	G=433	433	G	T						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.S2083_L2084delinsI	c.6248_6250delGTT	p.S2083_L2084delinsI			6512	orf1ab	ORF1ab		13196	0.0	13643			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	A=13195	13195	A	AGTT						False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.S3675del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'3676del', 'F3677del'	11287	orf1ab	ORF1ab		436	436.0	13643			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	G=436	436	G	GTCTGGTTTT						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.S371F	c.C1112T	p.S371F			22674	S	S	MISSENSE	430	436.0	13643						0	T=430	430	T	C						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.S371L	c.TC1111_1112CT	p.S371L			22673	S	S		13121	0.0	13643						0	CT=13118	13118	CT	TC						False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.S373P	c.T1117C	p.S373P			22679	S	S	MISSENSE	13563	436.0	13643						0	C=13563	13563	C	T	monoclonal antibody serial passage escape	Long et al. (2020)	https://doi.org/10.1128/mBio.02707-20		Reduce affinity for mildly cross-reactive CR3022 (2003 pandemic SARS monoclonal antibody cross-reactive to SARS-CoV-2)	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.S375F	c.C1124T	p.S375F			22686	S	S	MISSENSE	13131	0.0	13643						0	T=13131	13131	T	C						False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.S413R	c.A1237C	p.S413R			29510	N	N	MISSENSE	436	436.0	13643						1	C=435	435	C	A						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.S5360P	c.T16078C	p.S5360P			16342	orf1ab	ORF1ab	MISSENSE	435	436.0	13643			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	381	C=54	54	C	T						False	BA.2	BA.2=False	VOC		26-Nov-2021	24-Nov-2021
p.ST375FA	c.CCA1124_1126TCG	p.ST375FA			22686	S	S		430	436.0	13643						0	TCG=430	430	TCG	CCA						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.ST477NK	c.GCAC1430_1433ACAA	p.ST477NK			22992	S	S		9523	436.0	13643						0	ACAA=9520	9520	ACAA	GCAC						False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.T19I	c.C56T	p.T19I			21618	S	S	MISSENSE	435	436.0	13643						0	T=435	435	T	C						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.T223I	c.C668T	p.T223I			26060	ORF3a	ORF3a	MISSENSE	436	436.0	13643						0	T=436	436	T	C						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.T3090I	c.C9269T	p.T3090I			9534	orf1ab	ORF1ab	MISSENSE	436	436.0	13643			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	T=436	436	T	C						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.T3255I	c.C9764T	p.T3255I			10029	orf1ab	ORF1ab	MISSENSE	13643	436.0	13643			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	T=13643	13643	T	C						False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.T547K	c.C1640A	p.T547K			23202	S	S	MISSENSE	13183	0.0	13643						0	A=13183	13183	A	C						False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.T64T	c.C192T	p.T64T			25584	ORF3a	ORF3a	SILENT	13643	436.0	13643						0	T=13643	13643	T	C						False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.T6564I	c.C19691T	p.T6564I			19955	orf1ab	ORF1ab	MISSENSE	436	436.0	13643			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only	YP_009725310.1	0	T=436	436	T	C						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.T842I	c.C2525T	p.T842I			2790	orf1ab	ORF1ab	MISSENSE	436	436.0	13643			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=436	436	T	C						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.T95I	c.C284T	p.T95I			21846	S	S	MISSENSE	19729	0.0	13643						1	T=19728	19728	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.T95I	c.C284T	p.T95I			21846	S	S	MISSENSE	19729	0.0	13643						1	T=19728	19728	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.T95I	c.C284T	p.T95I			21846	S	S	MISSENSE	19729	0.0	13643						1	T=19728	19728	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.T9I	c.C26T	p.T9I			26270	E	E	MISSENSE	13581	436.0	13643						2	T=13579	13579	T	C	homoplasy	Borges et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1		In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent. 	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V11V	c.C33T	p.V11V			21595	S	S	SILENT	6569	0.0	13643						3446	T=3123	3123	T	C						False	BA.1.1	BA.1.1=False	VOC		26-Nov-2021	24-Nov-2021
p.V1750V	c.G5250T	p.V1750V			5515	orf1ab	ORF1ab	SILENT	6625	0.0	13643			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	5146	T=1479	1479	T	G						False	BA.1	BA.1=False	VOC		26-Nov-2021	24-Nov-2021
p.V1887I	c.G5659A	p.V1887I			5924	orf1ab	ORF1ab	MISSENSE	6623	0.0	13643			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	4624	A=1999	1999	A	G						False	BA.1	BA.1=False	VOC		26-Nov-2021	24-Nov-2021
p.V213G	c.T638G	p.V213G			22200	S	S	MISSENSE	436	436.0	13643						0	G=436	436	G	T						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.V3053V	c.A9159G	p.V3053V			9424	orf1ab	ORF1ab	SILENT	433	436.0	13643			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	G=433	433	G	A						False	BA.2	BA.2=True	VOC		26-Nov-2021	24-Nov-2021
p.V3782I	c.G11344A	p.V3782I			11609	orf1ab	ORF1ab	MISSENSE	6628	0.0	13643			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	5918	A=710	710	A	G						False	BA.1	BA.1=False	VOC		26-Nov-2021	24-Nov-2021
p.V4310V	c.T12930C	p.V4310V			13195	orf1ab	ORF1ab	SILENT	13207	0.0	13643			nsp10	nsp10_CysHis, formerly known as growth-factor-like protein (GFL), produced by both pp1a and pp1ab	YP_009725306.1	4	C=13203	13203	C	T						False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		13161	0.0	13643						1	TTA=13158	13158	TTA	CTATACATG	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'H69del'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis)."	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		13161	0.0	13643						1	TTA=13158	13158	TTA	CTATACATG	ACE2 receptor binding affinity	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'N501Y'	This mutation combination causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped  lentivirus, but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed. 	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		13161	0.0	13643						1	TTA=13158	13158	TTA	CTATACATG	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'H69del', 'N501Y'	Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		13161	0.0	13643						1	TTA=13158	13158	TTA	CTATACATG	antibody epitope effects	Rees-Spear et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1	'H69del'	Reduces neutralization by structurally unmapped mAb COVA1-21 (cluster XI).	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		13161	0.0	13643						1	TTA=13158	13158	TTA	CTATACATG	antibody epitope effects	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2	'H69del', 'N501Y'	Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x). PG: these effects are laregly missing in the deletion-alone data	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		13161	0.0	13643						1	TTA=13158	13158	TTA	CTATACATG	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'H69del'	1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. 	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		13161	0.0	13643						1	TTA=13158	13158	TTA	CTATACATG	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'H69del', 'N501Y', 'P681H'	One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		13161	0.0	13643						1	TTA=13158	13158	TTA	CTATACATG	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'H69del', 'N501Y', 'P681H'	Slight neutralization improvement on average in 16 health workers' convalescent sera.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		13161	0.0	13643						1	TTA=13158	13158	TTA	CTATACATG	convalescent plasma escape	Kemp et al. (2020)	https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v1		Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		13161	0.0	13643						1	TTA=13158	13158	TTA	CTATACATG	convalescent plasma escape	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2	'H69del'	Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		13161	0.0	13643						1	TTA=13158	13158	TTA	CTATACATG	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del'	Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		13161	0.0	13643						1	TTA=13158	13158	TTA	CTATACATG	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'N501Y', 'P681H'	These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		13161	0.0	13643						1	TTA=13158	13158	TTA	CTATACATG	environmental condition stability	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'N501Y', 'P681H'	Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		13161	0.0	13643						1	TTA=13158	13158	TTA	CTATACATG	immunosuppression variant emergence	Kemp et al. (2020)	https://doi.org/10.1101/2020.12.14.422555		The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7] Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		13161	0.0	13643						1	TTA=13158	13158	TTA	CTATACATG	symptom prevalence	Snell et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.16.21253377v1	'H69del', 'N501Y'	A higher proportion of cases infected with the B.1.1.7 variant were hypoxic on admission compared to other variants (70.0% vs 62.5%, p	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		13161	0.0	13643						1	TTA=13158	13158	TTA	CTATACATG	symptom prevalence	van Loon et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.15.21255389v1	'H69del', 'N501Y'	"In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P"	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		13161	0.0	13643						1	TTA=13158	13158	TTA	CTATACATG	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'N501Y'	Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, moreso than this combination with the addition of P681H.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		13161	0.0	13643						1	TTA=13158	13158	TTA	CTATACATG	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'N501Y', 'P681H'	Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		13161	0.0	13643						1	TTA=13158	13158	TTA	CTATACATG	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'H69del'	1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		13161	0.0	13643						1	TTA=13158	13158	TTA	CTATACATG	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'N501Y'	The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		13161	0.0	13643						1	TTA=13158	13158	TTA	CTATACATG	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'N501Y', 'P681H'	The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	BA.1.1, BA.1	BA.1=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.Y505H	c.T1513C	p.Y505H			23075	S	S	MISSENSE	13593	436.0	13643						0	C=13593	13593	C	T	anthropozoonotic events	McAloose et al. (2020)	https://dx.doi.org/10.1128/mBio.02220-20		Observed first in a single tiger (cohort of 5), potential adaptation.	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.Y505H	c.T1513C	p.Y505H			23075	S	S	MISSENSE	13593	436.0	13643						0	C=13593	13593	C	T	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.16 fold	False	BA.1.1, BA.1, BA.2	BA.1=True, BA.2=True, BA.1.1=True	VOC		26-Nov-2021	24-Nov-2021
